Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03442569
Title PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST